World Pharma News Digest - 21.05.2012

1 view
Skip to first unread message

Ruslan David

unread,
May 21, 2012, 5:30:31 AM5/21/12
to worldph...@googlegroups.com
Roche will report new data on important progress for people with advanced cancers at ASCO 2012
‎Roche (SIX: RO, ROG; OTCQX: RHHBY) will present important new data from studies of several of its cancer medicines at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), June 1 to 5, 2012, in Chicago.
Read more...
http://www.worldpharmanews.com/roche/2083-roche-will-report-new-data-on-important-progress-for-people-with-advanced-cancers-at-asco-2012
 
Amgen's BiTE® antibody blinatumomab (AMG 103) achieved high rate of complete response
‎Amgen (NASDAQ:AMGN) announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.
Read more...
http://www.worldpharmanews.com/amgen/2082-amgens-biter-antibody-blinatumomab-amg-103-achieved-high-rate-of-complete-response
 
Merck total revenues increase 3.2% to € 2.6 billion
‎The Merck Group's first-quarter 2012 total revenues rose 3.2% to € 2,645 million compared to € 2,564 million in the first quarter of 2011. Sales for the Group increased 3.5% to € 2,564 million in first quarter compared to € 2,478 million in the year-ago quarter.
Read more...
http://www.worldpharmanews.com/merckkgaa/2081-merck-total-revenues-increase-32-to--26-billion
 
Pfizer provides topline results from Phase 3 study of Torisel®
‎Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL® (temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT® (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.
Read more...
http://www.worldpharmanews.com/pfizer/2080-pfizer-provides-topline-results-from-phase-3-study-of-toriselr
 
In drug-approval race, US FDA ahead of Canada, Europe
‎The U.S. Food and Drug Administration (FDA) generally approves drug therapies faster and earlier than its counterparts in Canada and Europe, according to a new study by Yale School of Medicine researchers. The study counters perceptions that the drug approval process in the United States is especially slow.
Read more...
http://www.worldpharmanews.com/research/2079-in-drug-approval-race-us-fda-ahead-of-canada-europe
 
GlaxoSmithKline to fully acquire Cellzome for £61 million
‎GlaxoSmithKline plc (GSK) has entered into an agreement to acquire those shares it does not currently own in Cellzome, a leader in the development and advancement of proteomics technologies, for £61 million (US$99 million) in cash.
Read more...
http://www.worldpharmanews.com/gsk/2078-glaxosmithkline-to-fully-acquire-cellzome-for-p61-million
 
Bristol-Myers Squibb Foundation Announces $15 Million Expansion of Together on Diabetes® to China and India
‎The Bristol-Myers Squibb Foundation today announced the expansion of its Together on Diabetes® initiative to China and India, pledging $15 million over five years to help these developing nations with rapidly growing numbers of type 2 diabetes patients.
Read more...
http://www.worldpharmanews.com/bms/2077-bristol-myers-squibb-foundation-announces-15-million-expansion-of-together-on-diabetesr-to-china-and-india
 
Bristol-Myers Squibb and Tsinghua University Enter Strategic Partnership
‎Bristol-Myers Squibb Company (NYSE:BMY) and Tsinghua University of Beijing, China, today announced the formation of a multi-year strategic partnership. Under the agreement, Bristol-Myers Squibb will fund research efforts at Tsinghua University's School of Life Sciences to identify and validate novel targets in oncology and immunoscience.
Read more...
http://www.worldpharmanews.com/bms/2076-bristol-myers-squibb-and-tsinghua-university-enter-strategic-partnership
 
Blood pressure drugs don't protect against colorectal cancer
‎A new study has found that, contrary to current thinking, taking beta blockers that treat high blood pressure does not decrease a person's risk of developing colorectal cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study also revealed that even long-term use or subtypes of beta blockers showed no reduction of colorectal cancer risk.
Read more...
http://www.worldpharmanews.com/research/2075-blood-pressure-drugs-dont-protect-against-colorectal-cancer
 
Statistically significant clinical phase III results of Lu AA21004
‎H. Lundbeck A/S (Lundbeck) today announced positive top-line results from three recently completed phase III clinical studies of Lu AA21004, an investigational drug for the treatment of adults with major depressive disorder (MDD) using dosages from 10 to 20mg.
Read more...
http://www.worldpharmanews.com/lundbeck/2074-statistically-significant-clinical-phase-iii-results-of-lu-aa21004
 
PharmaNews.eu / Latest News
 
 
 
 
Abbott's XIENCE PRIME™ and XIENCE V® Drug Eluting Stents Receive Indication in Europe
http://www.pharmanews.eu/abbott/1055-abbotts-xience-prime-and-xience-vr-drug-eluting-stents-receive-indication-in-europe
 
GSK statement on BBC Panorama broadcast: 'the truth about tax'
http://www.pharmanews.eu/gsk/1054-gsk-statement-on-bbc-panorama-broadcast-the-truth-about-tax
 
 
 
With best regards,
Ruslan David
Administrator/Editor
 
 
PS: Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
http://www.worldpharmanews.com/contact-us
 
Reply all
Reply to author
Forward
0 new messages